SUBSCRIPTION AGREEMENTSubscription Agreement • August 3rd, 2017 • Sevion Therapeutics, Inc. • Services-commercial physical & biological research • Delaware
This Subscription Agreement (this “Agreement”) is being delivered to Pontifax (Cayman) III Limited Partnership, Pontifax (Israel) III Limited Partnership, Pontifax (Israel) IV Limited Partnership, Pontifax (Cayman) IV Limited Partnership and Pontifax (China) IV Limited Partnership (collectively, “Pontifax”), Dr. Phillip Frost (“Frost”), and additional investors as specified in Schedule A of this Agreement. Each of Pontifax, Frost, and the additional investors shall be referred hereinafter as the “Subscriber” and collectively the "Subscribers" in connection with their investment in the securities of Sevion Therapeutics, Inc., a Delaware corporation (the “Company”). The Company is conducting a private placement (the “Offering”) of up to Twelve Million Dollars ($12,000,000) of shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”) at a purchase price of $0.15 per share (the “Purchase Price”). For purposes of this Agreement, the term “Securities
